1
Gene M Bright: N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor. Pfizer, Charles J Knuth, Albert E Frost, Peter C Richardson, October 2, 1984: US04474768 (98 worldwide citation)

Antibacterial N-methyl 11-aza-10-deoxo-10-dihydroerythromycin A and pharmaceutically acceptable acid addition salts thereof, intermediates therefor, and processes for their preparation.


2
Gene M Bright, James R Hauske: Azahomoerythromycin D derivative and intermediates therefor. Pfizer, Charles J Knuth, Albert E Frost, Robert K Blackwood, August 14, 1984: US04465674 (18 worldwide citation)

Antibacterial 9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin D, pharmaceutically-acceptable salts thereof, pharmaceutical compositions comprising antibacterially-effective amounts thereof, a method of treatment of bacterial infections with antibacterially effective amounts thereof, and intermediates f ...


3
Gene M Bright: Epimeric azahomoerythromycin A derivative, intermediates and method of use. Pfizer, Charles J Knuth, Albert E Frost, Robert K Blackwood, July 2, 1985: US04526889 (16 worldwide citation)

Antibacterial 4"-epi-9-deoxo-9a-methyl-9a-aza-9a-homoerythromycin A, pharmaceutically-acceptable salts thereof, pharmaceutical compositions comprising antibacterially-effective amounts thereof, a method of treatment of bacterial infections with antibacterially effective amounts thereof, and intermed ...


4
Gene M Bright: Antibacterial cyclic ethers of 9-deoxo-9a-aza-9a-homoerythromycin A and intermediates therefor. Pfizer, Charles J Knuth, Albert E Frost, Peter C Richardson, January 8, 1985: US04492688 (14 worldwide citation)

Antibacterial 9,11-deoxo-11beta,9a-(epoxyalkano)9a-aza-9a-homoerythromycin A compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising antibacterially-effective amounts thereof and a pharmaceutically acceptable carrier, the treatment of bacterial infections with an ...


5
Gene M Bright, Kishor A Desai, Thomas F Seeger: Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines. Pfizer, Peter C Richardson, J Trevor Lumb, D Stuart McFarlin, October 20, 1992: US05157034 (9 worldwide citation)

Antipsychotic compounds having the formula ##STR1## wherein Z is H or Cl; Y is O or S; n is 1-4; separately, X is H or (C.sub.1 -C.sub.2)alkyl and L is R(CH.sub.2).sub.m CO, m is 0 or 1-3, R is (C.sub.1 -C.sub.6)alkyl, (C.sub.3 -C.sub.7)cycloalkyl, phenyl, naphthyl, furyl, benzofuranyl, thienyl, ben ...


6
Gene M Bright: Antibacterial 9-deoxo-9a-alkyl-9a-aza-9a-homoerythromycin A derivatives and intermediates therefore. Pfizer, Charles J Knuth, Albert E Frost, James M McManus, August 7, 1984: US04464527 (9 worldwide citation)

Antibacterial 9-deoxo-9a-ethyl and propyl-9a-aza-9a-homoerythromycin A compounds, pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising antibacterially effective amounts thereof and a pharmaceutically acceptable carrier, the treatment of bacterial infections with antibact ...


7
Gene M Bright, Kishor A Desai: Bis-aza-bicyclic anxiolytic agents. Pfizer, Peter C Richardson, J Trevor Lumb, D Stuart McFarlin, June 16, 1992: US05122525 (8 worldwide citation)

Anxiolytic agents which are racemic or optically active pyrido[1,2-a]pyrazine derivatives of the formula ##STR1## wherein x is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals; and intermediates therefor.


8
Gene M Bright: Heptanoyl-glu-asp-ala-amino acid immunostimulants. Pfizer, Peter C Richardson, Albert E Frost, Lawrence C Akers, July 25, 1989: US04851388 (8 worldwide citation)

Peptides useful as antiinfective agents, immunomodulators for stimulation of host defenses in patients with an increased risk of bacterial infections, intermediates and process therefor.


9
Gene M Bright, Willard M Welch Jr: Substituted pyrazoles as CRF antagonists. Pfizer, Peter C Richardson, Paul H Ginsburg, B Timothy Creagan, January 6, 1998: US05705646 (8 worldwide citation)

The compounds of the formula ##STR1## wherein A, R.sub.1, R.sub.3, Z and Y are as defined herein, have corticotropin-releasing factor (CRF) antagonist activity. They are useful in the treatment of illnesses induced by CRF, such as stress and anxiety related disorders.


10